（文章来源：证券日报） 证券日报网讯 1月29日，汉邦科技发布公告称，由于天健会计师事务所内部工作调整，现委派杨天将接 替吴慧作为签字注册会计师。变更后的签字注册会计师为朱俊峰和杨天将。 ...

江苏汉邦科技股份有限公司 证券代码：688755 证券简称：汉邦科技 公告编号：2026-003 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经江苏汉邦科技股份有限公司（以下简称"公司"）第一届董事会第十八 次会议和公司2024年年度股东大会审议通过，同意聘任天健会计师事务所（特 殊普通合伙）（以下简称"天健会计师事务所"）担任公司2025年度财务报表 和内部控制审计机构。 近日，公司收到天健会计师事务所出具的《关于变更签字注册会计师的函》， 现将具体情况公告如下： 一、本次变更签字注册会计师的基本情况 天健会计师事务所作为公司2025年度财务报表和2025年末财务报告内部控 制审计机构，原委派吴慧和朱俊峰作为公司2025年度财务报表审计报告和2025 年末财务报告内部控制审计报告的签字注册会计师。由于天健会计师事务所内部 工作调整，现委派杨天将接替吴慧作为签字注册会计师。变更后的签字注册会计 师为朱俊峰和杨天将。 二、本次变更签字注册会计师的基本信息 1.人员信息 签字注册会计师：杨天将，2 ...

分红方面，汉邦科技A股上市后累计派现880.00万元。 资料显示，江苏汉邦科技股份有限公司位于江苏省淮安经济技术开发区新竹路10号,淮安经济技术开发 区集贤路1-9号，成立日期1998年10月28日，上市日期2025年5月16日，公司主营业务涉及为制药、生命 科学等领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。主营业务收入构成 为：小分子药物分离纯化设备70.99%，大分子药物分离纯化设备22.94%，其他6.07%。 截至9月30日，汉邦科技股东户数8687.00，较上期减少7.31%；人均流通股1904股，较上期增加7.89%。 2025年1月-9月，汉邦科技实现营业收入5.06亿元，同比增长4.61%；归母净利润3701.72万元，同比减少 17.27%。 1月19日，汉邦科技跌0.10%，成交额1774.66万元。两融数据显示，当日汉邦科技获融资买入额152.72 万元，融资偿还445.62万元，融资净买入-292.90万元。截至1月19日，汉邦科技融资融券余额合计 6297.61万元。 融资方面，汉邦科技当日融资买入152.72万元。当前融资余额6291.74万元，占流通市值的 ...

证券代码：688755 证券简称：汉邦科技 公告编号：2026-002 江苏汉邦科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏汉邦科技股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日召开 第一届董事会第十九次会议和第一届监事会第十一次会议，审议通过了《关于使 用部分暂时闲置募集资金进行现金管理的议案》，同意公司（含实施募投项目的 子公司，下同）在确保不影响公司正常经营、不影响募集资金投资计划正常进行 及确保募集资金安全的前提下，使用最高不超过人民币 39,800.00 万元（单日最 高余额，含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动 性好的保本型产品（包括但不限于保本型理财产品、定期存款、通知存款、大额 存单、协定存款、结构性存款、收益凭证等）。在上述额度范围内，资金可以滚 动使用，使用期限自公司董事会审议通过之日起 12 个月内有效。具体内容详见公 司于上海证券交易所网站（www.sse.com.cn）披露的《关 ...

证券代码：688755 证券简称：汉邦科技 公告编号：2026-001 江苏汉邦科技股份有限公司 关于注销募集资金现金管理产品专用结算账户的公告 二、本次募集资金现金管理专用结算账户的注销情况 截至本公告披露日，公司在上述募集资金现金管理产品专用结算账户内的理 财产品已全部到期，现金管理专用结算账户内资金已全部赎回且在此账户无下一 步购买计划，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等相关规定，公司于近日办理完毕上述募集资金现金管理专用结算账户的注 销手续。具体账户信息如下： | 序号 | 账户名称 | 开户机构 | 资金账号 | 账户状态 | | --- | --- | --- | --- | --- | | 1 | 江苏汉邦科技股 | 兴业银行股份有限公司 | 402310100200343110 | 本次注销 | | | 份有限公司 | 淮安分行 | | | | 2 | 江苏汉邦科技股 | 中国建设银行股份有限公 | 32001725336049505688*219 | 本次注销 | | | 份有限公 ...

证券日报网讯 1月7日，汉邦科技在互动平台回答投资者提问时表示，公司工业制备液相色谱系统及相 关纯化设备，可广泛应用于生物医药（包括胰岛素、抗体、疫苗、抗生素等）的分离纯化环节。公司始 终密切关注下游市场需求变化，并积极把握市场机遇，具体订单情况请详见公司披露的定期报告。 ...

Group 1 - The article highlights the behavior of margin traders, indicating that investors are looking for investment opportunities through their activities [1] - On December 30, a total of 3,757 stocks received margin buying funds, with the top three stocks being Sanhua Intelligent Controls at 2.296 billion, Zhongji Xuchuang at 2.293 billion, and Xinyi Sheng at 1.910 billion [1] - Among the stocks with significant margin buying, 10 stocks had a margin buying amount that exceeded 30% of their total trading volume [1] Group 2 - The top stocks by margin buying amount and their respective trading volumes and percentages are detailed, with notable mentions including Qingtang City at 24.35 million and Daya Shengxiang at 12.86 million [2] - The data shows that the margin buying percentage for several stocks is high, with Qingtang City at 43.09%, Daya Shengxiang at 40.80%, and Guangming Meat Industry at 35.66% [1][2] - The article provides a comprehensive table listing various stocks, their margin buying amounts, total trading amounts, margin buying percentages, and daily price changes [1][2]

Core Insights - The article discusses the successful hosting of the "Qihang·2025 Financial Annual Conference" in Beijing, where Tang Yefeng, Vice President and Secretary of the Board of Jiangsu Hanbang Technology Co., Ltd. (Hanbang Technology), shared insights on the company's post-IPO development, core technology industrialization, domestic substitution progress in chromatography equipment, and the "14th Five-Year Plan" strategic layout [1][2]. Company Overview - Hanbang Technology, established in 1998, focuses on chromatography technology, integrating R&D, production, and sales, primarily serving the pharmaceutical and life sciences sectors with professional separation and purification equipment, consumables, and related solutions [3]. - The company has a leading position in the domestic chromatography separation and purification equipment market, holding a 39.2% market share in production-level small molecule separation and purification equipment, ranking first, and an 8.8% market share in large molecule equipment, ranking third [3]. IPO Impact - The IPO completed in May 2025 is viewed as a significant milestone, acting as an "accelerator" for high-quality development across three dimensions: enhancing capital strength, improving governance structure, and increasing resource integration capabilities [4]. - Funds raised from the IPO are directed towards projects such as the annual production of 1,000 liquid chromatography equipment and the establishment of a chromatography separation equipment R&D center, which will support capacity expansion and sales growth [4]. Value Communication - The role of the Secretary of the Board is crucial in conveying value for technology-intensive newly listed companies, focusing on translating complex technical systems into understandable market value propositions and establishing communication channels with investors [5]. Technological Advancements - Hanbang Technology has developed a unique technology system characterized by "one core, two nuclei, and multiple uses," focusing on core chromatography column technology and expanding into various product and service applications [6]. - The company is committed to continuous R&D investment and has established platforms such as provincial engineering research centers to tackle key technologies and enhance industrialization [6]. Domestic Substitution Progress - The domestic substitution of chromatography separation and purification equipment is at a critical stage, with Hanbang Technology leading in small molecule production equipment and accelerating its market share in large molecule equipment [7]. - The company has established three differentiated advantages: competitive product performance, localized service capabilities, and a comprehensive product line offering customized solutions [7]. Strategic Focus for the 14th Five-Year Plan - The "14th Five-Year Plan" emphasizes high-quality development and technological self-reliance, presenting significant opportunities for the biopharmaceutical upstream equipment industry [8]. - Hanbang Technology is focusing on three key areas: large molecule biopharmaceuticals, nucleic acid and peptide drugs, and the domestic substitution of chromatography fillers, aiming to break the monopoly of foreign brands [8].

12月26日，以"新开局、新动能、新征程"为主题的"启航·2025金融峰会"在北京圆满举办，大会由金融界主办，汇聚监管部门、行业协会、金融机构、上市 公司、媒体等领域数百位相关领导和重磅嘉宾。会上，第十四届金融界"金智奖"年度评选结果重磅揭晓，汉邦科技荣获"医药生物产业优胜奖"。 同时，汉邦科技的发展深度契合奖项"产业升级赋能"的核心要求，为生物医药产业高质量发展注入强劲动能。公司通过技术输出与产业链协同，带动上下游 配套企业技术升级，推动国内生物制药装备产业从"跟跑"向"并跑""领跑"跨越，助力构建自主可控的生物医药产业链生态。 展望未来，汉邦科技将持续坚守创新初心，加大核心技术研发投入，深耕高端生物制药装备核心赛道，进一步拓展细胞与基因治疗、合成生物学等新兴领域 的技术布局；将继续深化产业链协同合作，以更具突破性的技术成果赋能创新药研发与临床转化，让优质医疗资源惠及更多患者。在 "十五五" 健康中国战 略引领下，汉邦科技将以产业升级为己任，以技术创新为引擎，持续推动生物医药产业高质量发展，为医药强国建设注入持久动能。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：小讯 "金智奖"旨在树立高质量发展 ...

Group 1 - The core viewpoint of the news is that Hanbang Technology's stock performance and financial metrics indicate a mixed outlook, with slight revenue growth but a decline in net profit [1][2]. - On December 22, Hanbang Technology's stock fell by 0.05%, with a trading volume of 14.69 million yuan. The financing data shows a net buying of 1.29 million yuan for the day [1]. - As of December 22, the total balance of margin trading for Hanbang Technology was 74.60 million yuan, with the financing balance accounting for 10.64% of the circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Hanbang Technology was 8,687, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% [2]. - For the period from January to September 2025, Hanbang Technology achieved operating revenue of 506 million yuan, representing a year-on-year growth of 4.61%. However, the net profit attributable to the parent company decreased by 17.27% to 37.02 million yuan [2]. - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [2].